CARM1 and urinary bladder carcinoma: For bladder cancer, LA inhibited arginine methyltransferase (PRMT) activity in bladder cancer by targeting CARM1, thereby downregulating the expression of an epigenetic modification enzyme (Cheng and Bedford, 2011).